Navigation Links
Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
Date:2/12/2013

ash and equivalents, and we have no long-term debt. We believe our financial resources position us well for the future, and provide us with increased ability to consider promising opportunities that fit the criteria of our growth strategy."

Recent Highlights

  • In November 2012, the Company completed the public offering of 3,680,000 shares of class A common stock, which included 840,000 shares from selling stockholder El.En. S.p.A. The offering resulted in net proceeds of approximately $55.3 million to the Company.
  • The Company announced on December 4, 2012 that it received 510(k) clearance from the U.S. Food and Drug Administration to market the PicoSure™ laser workstation for the removal of tattoos and benign pigmented lesions. The Company expects to sell PicoSure initially through its U.S. direct sales force to aesthetic dermatologists and plastic surgeons. The Company plans to launch PicoSure in March 2013 at the Annual Meeting of the American Academy of Dermatology.

    • Business Outlook 
    "We capped a successful 2012 with our fifth consecutive quarter of profitability and record revenue on both a quarterly and full-year basis," Davin said. "We believe we enter 2013 poised for another year of profitable growth. We are excited for the launch of our newest flagship device, PicoSure, for the removal of tattoos and benign pigmented lesions.  After nearly a decade of research and development, this device provides us with a first-mover advantage in a large and underserved market. In addition, we expect that Cynosure's first home-use device, developed in partnership with Unilever, for the treatment of facial wrinkles will be commercially launched by Unilever in 2013." 

    Fourth-Quarter Financial Results Conference CallIn conjunction with the announcement of its fourth-quarter and year-end 2012 financial results, Cynosure will host a conference call for investors and an
    '/>"/>

    SOURCE Cynosure, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Cynosure Receives FDA Clearance for At-Home Device for the Treatment of Wrinkles
    2. Cynosure Announces Upcoming Conference Presentations
    3. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
    4. Cynosure, Inc. Prices Public Offering of Class A Common Stock
    5. Cynosure to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
    6. Cynosure to Host Fourth-Quarter 2012 Financial Results Conference Call on February 12
    7. Cynosure to Participate in Leerink Swann Global Healthcare Conference 2013
    8. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    9. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    10. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    11. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2013)... May 22, 2013 Varian Medical Systems ... received 510(k) clearance from the U.S. Food and ... processing workstation that combines radio frequency (RF) and ... Nexus DRF Digital X-Ray Imaging System™ has the ... receptors, including CCD cameras and commercially available flat-panel ...
    (Date:5/22/2013)... Cellular Biomedicine Group (OTCQB: CBMG) today announced that ... projected enrollment required for its Phase I trial to evaluate ... Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most ... had no Severe Adverse Effect (SAE) reported. The ... with NIH under number NCT01828762 (click here to view) ...
    (Date:5/22/2013)... , May 22, 2013 Rigel Pharmaceuticals, Inc. ... advancement of three programs in development. The first program ... inhibitor, R348, being developed by Rigel as a treatment ... aimed at oncology targets and are being conducted by ... by BerGenBio AS (BerGenBio) and a ligase inhibitor under ...
    Breaking Medicine Technology:Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System 2Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 2Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 2Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 4
    ... Chinese Medicines Company Announces Resignation of CFO, Effective December 2, 2010 -- SHENZHEN, China, Sept. 8 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // ...
    ... Decision Resources, one of the world,s leading ... issues, finds that increasing use of U.S. regulatory-approved ... Cymbalta/Xeristar (duloxetine) and Forest Laboratories, Savella (milnacipran) -- ... fibromyalgia drug market from 2009 to 2018. However, ...
    Cached Medicine Technology:Tongjitang Chinese Medicines Company Announces Resignation of CFO, Effective December 2, 2010 2Tongjitang Chinese Medicines Company Announces Resignation of CFO, Effective December 2, 2010 3Tongjitang Chinese Medicines Company Announces Resignation of CFO, Effective December 2, 2010 4Tongjitang Chinese Medicines Company Announces Resignation of CFO, Effective December 2, 2010 5Tongjitang Chinese Medicines Company Announces Resignation of CFO, Effective December 2, 2010 6Tongjitang Chinese Medicines Company Announces Resignation of CFO, Effective December 2, 2010 7Driven by Sales of Lyrica, Cymbalta/Xeristar and Savella, the Fibromyalgia Drug Market Will Experience 4.2 Percent Annual Growth Through 2018 2
    (Date:5/22/2013)... 2013 Spinal Elements, an innovative ... in Carlsbad to 3115 Melrose Drive, Suite 200, ... company’s continued and projected growth and has expanded ... feet to over 40,000 square feet. , ... indicated, “Our investment in these state-of-the-art facilities will ...
    (Date:5/22/2013)... Lawrenceville, NJ and Los Angeles, CA (PRWEB) May 22, ... chairman of the board, The J. M. Smucker Company, ... GS1 Lifetime Achievement Awards yesterday at the GS1 General ... Los Angeles, California. Mr. Smucker and Mr. Wegman were ... adoption of GS1 Standards - the most broadly used ...
    (Date:5/22/2013)... -- Children who are physically, sexually or emotionally abused ... in life, a new review suggests. British researchers ... to be obese as adults. They concluded that child ... for obesity. "We found that being maltreated as ... adult life," study author Dr. Andrea Danese, a child ...
    (Date:5/22/2013)... p53 turns off cancer. However, when existing drugs boost p53, only ... study published in the journal Cell Reports shows how: ... more of the protein p21 than the protein PUMA; tumors that ... the current study shows a handful of genes that control this ... mutated cancer genes. Tumors turn it off and then they can ...
    (Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine . , The U.S. ... in 2010 after a series of trials. These trials ... of pneumococcal types than the previously used PCV7, did ...
    Breaking Medicine News(10 mins):Health News:Spinal Elements®, Inc. Relocates Corporate Headquarters in Carlsbad 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Abused Children at Risk for Obesity as Adults: Study 2Health News:Study details genes that control whether tumors adapt or die when faced with p53 activating drugs 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2
    ... Inc. (Amex:,ULU) announced today that Ronald A. Ahrens has ... Mr. Ahrens has been an advisor to Merck ... of Merck Consumer Healthcare Group Worldwide.,He had previously served ... From 1985 to 1990 Mr. Ahrens was Consumer,Group President, ...
    ... 23 The American Society of,Transplantation (AST) recently ... Award, to Richard N. Fine, M.D. at the,American ... a,senior investigator whose lifelong work has advanced the ... the field and the,AST have been broad and ...
    ... clot-busting tPA, researchers say , , MONDAY, June 23 (HealthDay ... boost stroke patients, survival, new research suggests. , Gleevec, ... as chronic myelogenous leukemia (CML), will be tested to ... the side effects of the clot-dissolving drug tissue plasminogen ...
    ... and Public Health Experts to Raise Public ... Awareness Via Mobile Media, ... HIV testing is getting out to the general public, thanks to,the ... most reliable wireless voice and data network,announced today its continued effort ...
    ... 23 Boston Scientific,Corporation (NYSE: BSX ) today ... will help service veterans and the active armed forces,better ... has recently,passed the Veterans Mental Health Improvements Act, which ... originally introduced,by Senator Daniel Akaka (D-HI). The bill calls ...
    ... Therapeutic Vaccines for Infectious ... Diseases, ... on emerging understanding of the human immune system,today announced the closing of ... Partners, The Column Group and Versant,Ventures. The Column Group initially incubated the ...
    Cached Medicine News:Health News:ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors 2Health News:AST Awards Richard N. Fine, M.D. 2008 Ernest Hodge Distinguished Achievement Award 2Health News:Cancer Drug Gleevec Could Fight Stroke 2Health News:Cancer Drug Gleevec Could Fight Stroke 3Health News:Verizon Wireless Continues Support of National HIV Testing Awareness Campaign 2Health News:Verizon Wireless Continues Support of National HIV Testing Awareness Campaign 3Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 2Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 3Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 4Health News:Immune Design Announces $18 Million Series A Financing 2Health News:Immune Design Announces $18 Million Series A Financing 3
    ... Oximeter with SAC (Serial Autocorrelation) Technology uses ... extract SpO 2 , pulse strength, and ... This cost-effective compact monitor incorporates clinical, ... features, and a data log or trend ...
    ... Autocorr Plus, the fourth in the ... pulse oximeter/ECG/Respiration Monitor, with 3 or ... oximetry with SAC (Serial Autocorrelation) technology, ... screen display provides two user configurable ...
    ... The BCI 3180 Pulse Oximeter is a ... SpO 2 pulse rate and pulse ... adult. This AC or battery powered ... low alarm limits and up to 30 ...
    ... ReZoom intraocular lens is a second-generation refractive ... with greater independence from glasses than monofocal ... a range of vision that monfocals cannot ... technology distributes light over five optic zones ...
    Medicine Products: